7-甲基-4-氧代-4H-吡啶并[1,2-a]嘧啶-3-羧酸乙酯 | 5435-82-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 中文名称: 7-甲基-4-氧代-4H-吡啶并[1,2-a]嘧啶-3-羧酸乙酯
• 英文名称: ethyl 7-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylate
• 英文别名: ethyl 7-mehyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylate；7-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylic acid ethyl ester；7-Methyl-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-carbonsaeure-aethylester；ethyl 7-methyl-4-oxopyrido[1,2-a]pyrimidine-3-carboxylate
• CAS: 5435-82-5
• 化学式: C₁₂H₁₂N₂O₃
• 分子量: 232.239
• InChiKey: LVRKSDQLEQQBHH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  59
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 7-methyl-4-oxopyrido[1,2-a]pyrimidine-3-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 7-methyl-4-oxopyrido[1,2-a]pyrimidine-3-carboxylate
CAS number: 5435-82-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H12N2O3
Molecular weight: 232.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  7-甲基-4-氧代-4H-吡啶并[1,2-a]嘧啶-3-羧酸乙酯 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 以78%的产率得到ethyl 7-methyl-4-oxo-tetrahydropyrido<1,2-a>pyrimidine-3-carboxylate
  参考文献：
  名称：

  Horvath, Agnes; Hermecz, Istvan; Vasvari-Debreczy, Lelle, Journal of the Chemical Society. Perkin transactions I, 1983, # 2, p. 369 - 378

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氨基-5-甲基吡啶 以 四氢呋喃 、 乙醇 为溶剂， 130.0~390.0 ℃ 、10.0 MPa 条件下， 反应 0.17h， 生成 7-甲基-4-氧代-4H-吡啶并[1,2-a]嘧啶-3-羧酸乙酯
  参考文献：
  名称：

  在自动化的高温高压流动反应器中合成熔融的嘧啶酮和喹诺酮衍生物

  摘要：

  在自动化的Phoenix高温高压连续流反应器中，数分钟之内即可合成出对药物研究潜在感兴趣的熔融嘧啶酮和喹诺酮衍生物，收率高达96％。难于合成或需要多步操作的杂环支架可使用一组常见的反应条件轻松获得。低沸点溶剂的使用以及这些反应的高转化率使得易于后处理和分离。本文报道的方法高度适合于快速和有效的杂环合成以及化合物的放大。

  DOI：

  10.1021/acs.joc.6b02520

文献信息

• On the Regioselectivity of the Gould–Jacobs Reaction: Gas‐Phase Versus Solution‐Phase Thermolysis
  作者：Michaela Wernik、Peter E. Hartmann、Gellért Sipos、Ferenc Darvas、A. Daniel Boese、Doris Dallinger、C. Oliver Kappe

  DOI：10.1002/ejoc.202001110

  日期：2020.12.7

  The regioselectivity of the Gould–Jacobs reaction of (pyridyl)aminomethylenemalonates can be controlled either in favor of the kinetic (pyridopyrimidinone) or the thermodynamic (naphthyridinone) product, depending on the position of the substituent in the pyridine moiety and the applied thermolysis technique.

  （吡啶基）氨基亚甲基丙二酸酯的古尔德-雅各布斯反应的区域选择性可以控制为动力学的（吡啶并嘧啶酮）或热力学的（萘啶酮）产物，这取决于取代基在吡啶部分中的位置和所应用的热解技术。
• Substituted amide derivatives and methods of use
  申请人：Kim Tae-Seong

  公开号：US20080312232A1

  公开（公告）日：2008-12-18

  Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  所选化合物对于预防和治疗疾病，如HGF介导的疾病具有有效性。本发明涵盖了新型化合物、类似物、前药及其药学上可接受的盐、药物组合物和用于预防和治疗涉及癌症等疾病和其他疾病或状况的方法。本发明还涉及制备这些化合物的过程，以及在这些过程中有用的中间体。
• METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES
  申请人：KIM Tae-Seong

  公开号：US20120070413A1

  公开（公告）日：2012-03-22

  Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选定的化合物对于预防和治疗疾病，如HGF介导的疾病非常有效。本发明包括新颖的化合物、类似物、前药和其药学上可接受的盐、制药组合物以及用于预防和治疗涉及癌症等疾病和其他疾病或情况的方法。本发明还涉及制备这些化合物的过程以及在这些过程中有用的中间体。
• SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE
  申请人：Kim Tae-Seong

  公开号：US20110118252A1

  公开（公告）日：2011-05-19

  Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  选定的化合物对于预防和治疗疾病，如HGF介导的疾病具有有效性。该发明包括新型化合物、类似物、前药和其药学上可接受的盐、药物组合物以及预防和治疗癌症等疾病和其他疾病或状况的方法。本发明还涉及制备这些化合物的过程以及在这些过程中有用的中间体。
• Method of treating cancer with substituted amide derivatives
  申请人：Kim Tae-Seong

  公开号：US08685983B2

  公开（公告）日：2014-04-01

  Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

  所选化合物对于预防和治疗疾病，如HGF介导的疾病具有有效性。该发明涵盖了新颖的化合物、类似物、前药和其药学上可接受的盐、药物组合物以及用于预防和治疗包括癌症等疾病和其他疾病或病症的方法。该发明还涉及制备这些化合物的过程以及在这些过程中有用的中间体。